Objective-The leukotriene B 4 (LTB 4 ) receptor BLT2 is expressed in endothelium, but no clear physiological function for it has yet been identified, especially in vascular angiogenesis. The purpose of this study is to characterize the potential function of BLT2 in vascular endothelial growth factor (VEGF)-induced angiogenesis. Methods and Results-VEGF significantly upregulates BLT2 expression in human umbilical vein endothelial cells (HUVECs), and BLT2 knockdown by siRNA or inhibition of BLT2 by a specific BLT2 antagonist LY255283 attenuates VEGF-induced angiogenesis, which was determined by its effect on the formation of tube-like structures and on transmigration. The role of BLT2 in VEGF-induced angiogenesis was more evident in vivo, where BLT2 inhibition by LY255283 almost completely blocked VEGF-induced vessel formation in Matrigel-plug assays. In addition, we found that VEGF upregulates synthesis of the BLT2 ligand, 12(S)-hydroxyeicosatetraenoic acid (HETE). siRNA knockdown of 12-lipoxygenase (12-LO) expression attenuates VEGF-induced angiogenesis in HUVECs, and the addition of 12(S)-HETE to the 12-LO knockdown-HUVECs restores VEGF-induced angiogenesis. The activation of BLT2 itself by either 12(S)-HETE or LTB 4 evoked significant angiogenic phenotypes, both in vitro and in vivo. Conclusion-Our findings indicate that BLT2 plays an essential role in mediating VEGF-induced angiogenesis. (Arterioscler Thromb Vasc Biol. 2009;29:915-920.)
A ngiogenesis is the formation of new blood vessels from preexisting ones, which is crucial for the development and progression of solid tumors. 1 Within the tumor microenvironment, the balance between the activities of pro-and antiangiogenic factors tightly regulates angiogenesis. 2 The best characterized and most potent of the proangiogenic factors is vascular endothelial growth factor (VEGF). 3 The binding of VEGF to its receptors (VEGFRs), particularly VEGFR2, which is found predominantly on endothelial cells, triggers a range of signaling processes that evoke vascular endothelial cell growth, migration, survival, and permeability. 3 In addition to VEGF, arachidonic acid (AA) metabolites, which are collectively known as eicosanoids, are also involved in regulating both tumorigenesis and angiogenesis. 4 Once released by cytosolic phospholipase A 2 (cPLA 2 ), 5 AA is further metabolized via the cyclooxygenase (COX), lipoxygenase (LO), and cytochrome P450-dependent pathways. The COX2-catalyzed production of prostaglandins from AA promotes angiogenesis and increases metastatic potential, which suggests a role for COX2 in tumor angiogenesis. 6 AA metabolites generated via the LO pathway, which include leukotrienes (LTs) and hydroxyeicosatetraenoic acids (HETEs), are also involved in tumor angiogenesis. The 12-LO product, 12(S)-HETE, has been reported to enhance both angiogenesis and tumor growth. 7, 8 However, the role of 12(S)-HETE in VEGF-induced angiogenesis and the specific receptor that mediates the actions of 12(S)-HETE remain unknown. The role of LTs in angiogenesis is even less well characterized than that of HETEs. LTB 4 , which is the first leukotriene to be isolated, has potent chemotactic activity toward granulocytes and T lymphocytes, 9 -11 and overexpression of LTB 4 is involved in inflammation-related diseases, such as bronchial asthma and rheumatoid arthritis. 12, 13 Recently, an enhanced production of LTB 4 was noted in Ras-transformed cells, 14 which suggested a possible role for LTB 4 in tumor progression. LTB 4 exerts its biological effects through two distinct receptors, BLT1 and BLT2. 15, 16 Most studies have focused on the high-affinity receptor, BLT1, which is expressed exclusively in inflammatory cells, such as leukocytes, and plays a key role in inflammatory processes. 13, 15, 17 In contrast, BLT2, which is a low-affinity receptor for LTB 4 , is expressed in a wide variety of tissues, including the endothelium. 14, 16, 18, 19 Although no clear physiological function has yet been identified for BLT2, recent studies have demonstrated that it regulates the migration of mast cells, keratinocytes, and dendritic cells. 20 -22 Because BLT2 is known to interact with both LTB 4 and 12(S)-HETE, 23 it could potentially mediate the actions of both of these ligands in vivo. In the present study, we assessed the potential function of BLT2 in VEGF-induced angiogenesis. Our findings indicate that BLT2 expression is highly induced by VEGF and that the induced BLT2 plays an essential role in mediating VEGF-induced angiogenesis, which suggests a potential interplay among VEGF, BLT2, and BLT2 ligands in vascular angiogenesis.
Methods
All of the experiments were performed using human umbilical vein endothelial cells (HUVECs) and FVB mice. All experimental animals used in this study were treated according to guidelines approved by the Institutional Animal Care and Use Committee of Korea University. The detailed descriptions of the methods that were used in this study are provided in the supplemental materials (available online at http://atvb.ahajournals.org).
Results

A BLT2-Linked Pathway Is Necessary for VEGF-Induced Angiogenesis
To investigate the possible role of the BLTs in VEGFinduced angiogenesis, we initially used real-time PCR, semiquantitative RT-PCR, and FACS analysis to examine the effect of VEGF on BLT expression in HUVECs. Incubation of the cells with VEGF (20 ng/mL) led to an upregulation of both BLT1 and BLT2 mRNA ( Figure 1A and 1B) and a corresponding increase in the expression of the BLT proteins ( Figure 1C ).
VEGF is known to induce angiogenesis both in vivo and in vitro. 3 Therefore, we next used Matrigel-plug assays to determine the extent to which the observed upregulation of BLT expression is necessary for VEGF-induced angiogenesis in vivo. When VEGF and growth factor-reduced Matrigel were subcutaneously injected into mice, there was a significant induction of new blood vessel formation over the course of 7 days. This was confirmed by positive staining for vascular endothelial cadherin (VE-Cadherin), which is a specific endothelial marker ( Figure 2A ). Notably, simultaneous injection of LY255283, which is a specific BLT2 antagonist, dramatically reduced blood vessel formation, whereas simultaneous injection of U75302, which is a BLT1 antagonist, had little effect ( Figure 2A ). We also examined the effects of these BLT inhibitors on the formation of VEGF-induced tube-like structures in vitro. When HUVECs were plated on Matrigel in the presence of VEGF, networks of tube-like structures were formed. Consistent with the in vivo findings, this effect was diminished by pretreatment with LY255283 but not pretreatment with U75302 (supplemental Figure IA ). We used Transwell chambers to test the effect of the BLT inhibitors on VEGF-induced transmigration and found that pretreatment with LY255283, but not U75302, significantly reduced VEGF-induced transmigration (supple-mental Figure IB) . These observations were also confirmed by siRNA knockdown of BLT2. When BLT2 siRNA (50 nmol/L) was introduced into HUVECs, the level of BLT2 mRNA was specifically reduced ( Figure 2B ). This knockdown of BLT2 expression reduced both the formation of VEGF (20 ng/mL)-induced tube-like structures and the transmigration ( Figure 2C and 2D). Based on these results, we conclude that VEGF-induced angiogenesis is considerably mediated via a BLT2-linked pathway.
12(S)-HETE Is Involved in Mediating VEGF-Induced Angiogenesis
We then wanted to determine whether VEGF could induce the synthesis of the 2 known BLT2 ligands, 12(S)-HETE and LTB 4 . 23 Platelet-type 12-LO had been previously reported to be expressed in HUVECs. 24 In the present study, we observed that VEGF (20 ng/mL) upregulated both the expression of platelet-type 12-LO (data not shown) and the synthesis of 12(S)-HETE ( Figure 3A ). In contrast, VEGF had no effect on LTB 4 synthesis in HUVECs. In addition, VEGF did not induce the expression of 5-LO or 5-LO activating protein (FLAP), which suggests that LTB 4 is not involved in mediating VEGF signaling, at least in vitro (supplemental Figure II ). Figure III) . Thus, 12-LO, its product 12(S)-HETE, and its involvement in the BLT2 pathway appear to play critical roles in mediating VEGF-induced angiogenesis.
Activation of the BLT2 Pathway Is Sufficient to Induce Angiogenesis
We then wanted to determine whether stimulation of BLT2 alone, or by treatment with LTB 4 or 12(S)-HETE, could induce angiogenesis. Because HUVECs express only low levels of BLT2 under basal conditions, 19 we induced BLT2 expression by pretreating HUVECs with VEGF for 9 hours ( Figure 1C ) and then assessed transmigration and the formation of tube-like structures under those conditions. When cells were stimulated with LTB 4 (300 nmol/L) or 12(S)-HETE (100 nmol/L), transmigration and the formation of tube-like structures were greatly increased in the VEGF-pretreated group, although they were also increased somewhat in control cells pretreated with vehicle (PBS). Once again, LY255283, but not U75302, significantly reduced these effects (supplemental Figure IV) , which suggested a specific mediatory role for BLT2. Similarly, BLT2 knockdown by siRNA caused significantly reduced angiogenesis in the VEGF-pretreated group (Figure 4A and 4B ). We also enhanced BLT2 expression by transfecting HUVECs with a BLT2 expression plasmid using Lipofectamine reagent ( Figure 4C ) and carried out the same assays using the transfectants. We found that the activation of BLT2 by LTB 4 (300 nmol/L) or 12(S)-HETE (100 nmol/L) greatly enhanced angiogenic phenotypes in BLT2 transfectants when compared with HUVECs transfected with the empty vector ( Figure 4D and 4E ). This indicates that BLT2 stimulation is sufficient to cause angiogenesis and that BLT2 is the receptor responsible for angiogenesis induced by 12(S)-HETE or LTB 4 .
Enhanced Blood Vessel Formation in BLT2-Overexpressing Transgenic Mice
To further assess the role of BLT2 in angiogenesis, BLT2 transgenic (TG) mice were prepared using the pCAGGS-B2 vector. After confirming proper BLT2 gene insertion, semiquantitative RT-PCR was carried out to verify the presence of elevated levels of BLT2 mRNA in the TG mice (supplemental Figure V) . We then subcutaneously injected LTB 4 and 12(S)-HETE together with growth factor-reduced Matrigel into wild-type (WT) and BLT2 TG mice. After 7 days, new blood vessel formation was dramatically increased in the Figure  1C ) and then LTB 4 -or 12(S)-HETE-induced transmigration assay and tube-like structure formation assay were performed. nϭ3. C, HUVECs were transfected with pcDNA3 or pcDNA3-human BLT2, after which semiquantitative RT-PCR was carried out. D and E, LTB 4 -or 12(S)-HETE-induced transmigration assay and tube-like structure formation assay were performed on HUVECs transfected with pcDNA3 or pcDNA3-human BLT2. nϭ3.
BLT2 TG mice compared with the WT mice ( Figure 5 ). Notably, simultaneous injection of the BLT2 antagonist, LY255283, almost completely blocked new blood vessel formation in the BLT2 TG mice as well as in WT mice ( Figure 5 ). This further demonstrated the critical role of BLT2 in angiogenesis.
Discussion
In the present study, we demonstrated that the induction of BLT2 expression and the stimulation of a BLT2-linked pathway are critical for VEGF-induced angiogenesis. VEGF stimulated the expression of BLT2 and BLT1 (Figure 1) , and the inhibition of BLT2, but not BLT1, interfered with VEGF-induced angiogenesis in HUVECs (Figure 2 ). The role of BLT2 in VEGF-induced angiogenesis is more evident in vivo, where LY255283 almost completely suppressed VEGFinduced vessel formation in a Matrigel-plug assay (Figure 2 ). In addition, VEGF upregulated the synthesis of 12(S)-HETE, which is a BLT2 ligand in HUVECs. 12-LO knockdown by siRNA attenuated VEGF-induced angiogenesis (Figure 3) . Consistent with the potential role of BLT2 in VEGF-induced angiogenesis, the stimulation of BLT2 with its specific ligands, 12(S)-HETE or LTB 4 , caused significant angiogenic activity (Figure 4) . Importantly, BLT2 transgenic mice had greatly enhanced angiogenic phenotypes when they were challenged with BLT2 ligands (Figure 5) , which again supported a potential role for BLT2 in angiogenesis.
Throughout these experiments, the contribution of BLT2 to VEGF-induced angiogenesis has been more pronounced in vivo than in vitro. For example, BLT2 knockdown by siRNA or inhibition of BLT2 by LY255283 suppressed the angiogenic phenotypes induced by VEGF to a much greater extent in vivo than in vitro (Figure 2 and supplemental Figure I) , which suggests the former is much more dependent on the BLT2 pathway. We do not know the reasons for the difference between the in vitro and in vivo findings, but we suggest that the BLT2-linked pathway might be more effectively stimulated in vivo, perhaps because of the augmented production of 12(S)-HETE or LTB 4 in the angiogenic area. In fact, the levels of 12(S)-HETE and LTB 4 are reportedly increased at sites of tumor angiogenesis, and many tumor cells overexpress 12-LO, 5-LO or LTA 4 hydrolase. 26 -28 In addition, we found that various types of tumor tissues express higher levels of BLT2 than their corresponding normal tissues (supplemental Figure VI) . Therefore, those tumors are likely to produce elevated levels of the BLT2 ligands. The synthesis of LTB 4 and 12(S)-HETE is somehow induced when BLT2 expression is upregulated such that each induced the expression of the other in an autocrine manner, 14 which is consistent with reports of similar cross-talk among eicosanoid lipid ligands and their receptors. 29 In addition to tumor cells, an elevated production of the BLT2 ligands may be also derived from infiltrating leukocytes. The BLT2 ligands, especially the well-known chemoattractant for leukocytes, LTB 4 , 10, 11, 30 may recruit leukocytes to the angiogenic vessel area, and these cells may produce elevated levels of 12(S)-HETE or LTB 4 . 31 Consistent with this idea, highly induced neutrophils, which stained with the neutrophil-specific anti-Gr-1 antibody, accumulated in the matrigels that were treated with 12(S)-HETE or LTB 4 in the in vivo angiogenesis assays (supplemental Figure VII) . It has been reported that neutrophils, which are the most abundant leukocyte present in the blood, regulate angiogenesis. 32 Using F4/80 staining, we also investigated macrophage involvement, and there was only a slightly increased infiltration of macrophages into the matrigels in the presence of 12(S)-HETE or LTB 4. These results suggested that the contributory role of macrophages is likely to be minimal (data not shown). Given that BLT2 activation is suggested to occur downstream of VEGF, VEGF may also recruit leukocytes around the VEGF-secreting angiogenic area. As expected, there was an extensive accumulation of neutrophils within the plugs that were treated with VEGF, and there were no neutrophils within the plugs that were treated with PBS (supplemental Figure VIII) . These observations are consistent with the finding that VEGF recruits myeloid progenitor cells, monocytes, and neutrophils to regions of ongoing angiogenesis. 33 These cells likely produce 12(S)-HETE or LTB 4 , which further potentiates angiogenesis via the BLT2-linked cascade in endothelium. We speculate that the upregulation of BLT2 expression and the stimulation of the BLT2 signaling pathway in response to the elevated production of 12(S)-HETE or LTB 4 both likely play a crucial role in angiogenesis in vivo. Recently, another BLT2 ligand, 12(S)-hydroxyheptadeca-5Z, 8E, 10E-trienoic acid (12-HHT), was identified. 34 12-HHT is one of the products of thrompoxane A 2 synthase and is found in tissues and bodily fluid. 34 The function of 12-HHT is not yet clear, and the role of 12-HHT in inducing angiogenesis via the BLT2 pathway remains to be characterized.
In contrast to the in vivo situation, the production of BLT2 ligands may be relatively limited in the in vitro HUVEC culture system. We detected an approximately 1.4-fold increase in the synthesis of 12(S)-HETE in HUVECs stimulated with VEGF ( Figure 3A ), but we did not detect any accumulation of LTB 4 (supplemental Figure IIA) . HUVECs do not express FLAP, and VEGF did not induce its expression (supplemental Figure IIB and IIC) . Therefore the inhibition of VEGF-induced angiogenesis by BLT2 siRNA or LY255283 in vitro is likely attributable to a block in the interaction of 12(S)-HETE with BLT2. In the same way, 12-LO siRNA or baicalein caused an inhibition of VEGFinduced angiogenesis, and the addition of supplemental 12(S)-HETE abolished their inhibitory effect on angiogenic responses ( Figure 3C and 3D and supplemental Figure III) . The synthesis of 12(S)-HETE by 12-LO and its autocrine/ paracrine action via BLT2 may therefore be implicated in VEGF-induced angiogenesis in vitro. VEGF has been reported to stimulate platelet-type 12-LO activity and induce the synthesis of 12(S)-HETE in an RV-ECT endothelial cell line, which was derived from rat brain microvessels, in the presence of exogenously added AA. 24 In addition, the overexpression of 12-LO has been shown to increase the accumulation of VEGF in prostate cancer cells. 25 There appears to be cross-talk between VEGF and 12-LO, such that each triggers the induction of the other. We could not, however, detect the induction of VEGF in response to treatment with 12(S)-HETE in HUVECs (data not shown).
The mechanism by which BLT2 stimulates angiogenesis remains to be further characterized, but our findings suggest that inhibition of the ERKs specifically interferes with BLT2induced angiogenesis, such as by inhibiting HUVECs proliferation (supplemental Figure IX) . This implies that ERKs occur downstream of BLT2 21 during angiogenesis. We have created a model that depicts how BLT2 and its ligands form an integrated pathway that affects VEGF signaling ( Figure 6 ). In this model, VEGF-activated endothelial cells upregulate BLT2 expression and synthesize its ligand, 12(S)-HETE. This process would enhance angiogenesis through an autocrine/ paracrine mechanism. In addition, infiltrating leukocytes may produce more 12(S)-HETE or LTB 4, which would further stimulate the BLT2 cascade and potentiate angiogenesis. Based on these data, we speculate that there is a self-reinforcing signaling network in the angiogenic microenvironment that involves VEGF-secreting cells (eg, tumor cells), BLT2overexpressing endothelium, and leukocyte-derived expres-sion of LTB 4 /12(S)-HETE, and together they lead to fully activated angiogenesis. In summary, our findings point to BLT2 as a key mediator of VEGF signaling, and contribute to a better understanding of the mechanism responsible for vascular angiogenesis. 
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